A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Topline phase 3 results show retatrutide led to meaningful weight reduction and pain relief in adults with overweight or obesity and knee OA.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Knee pain often results from injuries to muscles, tendons, or ligaments. Deep vein thrombosis is a severe condition that can cause pain behind your knee. Most minor knee injuries can heal on their own ...

Eli Lilly’s “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with ...

Eli Lilly drug candidate retatrutide achieved up to 28.7% weight loss and reduced knee osteoarthritis pain in a phase 3 trial of 445 adults.